Geode Capital Management, LLC Cyclo Therapeutics, Inc. Transaction History
Geode Capital Management, LLC
- $1.26 Trillion
- Q4 2024
A detailed history of Geode Capital Management, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 152,332 shares of CYTH stock, worth $115,772. This represents 0.0% of its overall portfolio holdings.
Number of Shares
152,332
Previous 152,332
-0.0%
Holding current value
$115,772
Previous $120,000
28.33%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CYTH
# of Institutions
21Shares Held
2.24MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA689KShares$523,9790.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$455,0070.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$365,33816.84% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$83,617100.0% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$45,2270.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.41M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...